Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Jul 30, 2015
Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target
Jun 25, 2015
Heptares StaR® Technology and its Impact on GPCR Drug R&D featured in New Report Celebrating UK Bioscience from the UK BioIndustry Association

Aug 16-20, 2015
American Chemical Society National Meeting
Boston, MA, USA
Presenting: Jon Mason

Sep 15-17, 2015
BioPharm America
Boston, MA, USA
Attending: Dan Grau

© 2012-2015 Heptares Therapeutics